Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has been given a consensus rating of “Hold” by the eleven research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $22.29.

Several equities analysts recently weighed in on the stock. Northland Securities reaffirmed a “buy” rating and set a $28.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, March 5th. ValuEngine raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, February 7th. BidaskClub raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, February 25th. Finally, Piper Jaffray Companies set a $23.00 target price on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 5th.

Shares of NASDAQ ADMS traded down $0.19 during midday trading on Monday, reaching $6.25. The stock had a trading volume of 7,265 shares, compared to its average volume of 436,887. The company has a debt-to-equity ratio of 1.31, a current ratio of 9.41 and a quick ratio of 9.20. The stock has a market cap of $175.41 million, a PE ratio of -1.29 and a beta of 1.43. Adamas Pharmaceuticals has a 12-month low of $6.37 and a 12-month high of $32.90.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Monday, March 4th. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.36) by $0.30. The firm had revenue of $13.32 million during the quarter, compared to analysts’ expectations of $13.30 million. Adamas Pharmaceuticals had a negative net margin of 384.77% and a negative return on equity of 101.46%. On average, research analysts expect that Adamas Pharmaceuticals will post -4.14 EPS for the current year.

In other Adamas Pharmaceuticals news, CEO Gregory T. Went sold 6,319 shares of Adamas Pharmaceuticals stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $7.99, for a total value of $50,488.81. Following the completion of the transaction, the chief executive officer now directly owns 176,291 shares of the company’s stock, valued at approximately $1,408,565.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 8,361 shares of company stock valued at $66,816 over the last three months. Corporate insiders own 24.60% of the company’s stock.

Several large investors have recently modified their holdings of ADMS. First Mercantile Trust Co. lifted its holdings in shares of Adamas Pharmaceuticals by 43.2% in the 4th quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock worth $49,000 after acquiring an additional 1,740 shares during the last quarter. Advisor Group Inc. lifted its holdings in shares of Adamas Pharmaceuticals by 252.0% in the 4th quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 4,510 shares during the last quarter. Pacer Advisors Inc. bought a new stake in shares of Adamas Pharmaceuticals in the 3rd quarter worth about $104,000. Barclays PLC lifted its holdings in shares of Adamas Pharmaceuticals by 87.6% in the 4th quarter. Barclays PLC now owns 17,387 shares of the specialty pharmaceutical company’s stock worth $148,000 after acquiring an additional 8,118 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Adamas Pharmaceuticals in the 4th quarter worth about $161,000. 88.28% of the stock is owned by institutional investors and hedge funds.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Further Reading: What strategies should day traders use to execute a trade?

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.